# Assessment of the WATCHMAN™ Device in Patients Unsuitable for Oral Anticoagulation

Study · id `cardio:ct-nct02928497` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT02928497](<https://clinicaltrials.gov/study/NCT02928497>), retrieved 18 November 2026. No person wrote or checked this page.

Also called: NCT02928497

Browse, organ or system: Brain  
Browse, condition area: Stroke  

## In plain language

A trial with no phase registered on ClinicalTrials.gov. The registry status is terminated. It enrolled 481 participants.

## Technical summary

Registry record NCT02928497. Randomized; no masking; primary purpose prevention. Start 2017-02-06 (actual); primary completion 2025-09-23 (actual). Results posted on 2026-08-25.

## Key facts

- Design: Interventional study; randomized; no masking; primary purpose prevention
- Phase: Not applicable
- Enrolled: 481 participants (enrolled count; ClinicalTrials.gov record NCT02928497, source copy `cardio:ctgov-nct02928497-2026-08-25`, retrieved 2026-11-18)
- Started: 2017-02-06 (actual) (ClinicalTrials.gov record NCT02928497, source copy `cardio:ctgov-nct02928497-2026-08-25`, retrieved 2026-11-18)
- Primary completion: 2025-09-23 (actual) (ClinicalTrials.gov record NCT02928497, source copy `cardio:ctgov-nct02928497-2026-08-25`, retrieved 2026-11-18)
- Completion: 2025-09-23 (actual) (ClinicalTrials.gov record NCT02928497, source copy `cardio:ctgov-nct02928497-2026-08-25`, retrieved 2026-11-18)
- Results first posted: 2026-08-25 (ClinicalTrials.gov record NCT02928497, source copy `cardio:ctgov-nct02928497-2026-08-25`, retrieved 2026-11-18)
- Countries: United States; Belgium; Canada; Czechia; Denmark; Germany; Italy; Netherlands; United Kingdom (ClinicalTrials.gov record NCT02928497, source copy `cardio:ctgov-nct02928497-2026-08-25`, retrieved 2026-11-18)
- Care setting: Not reported
- Registry status: "TERMINATED" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct02928497-2026-08-25`, retrieved 2026-11-18)

## The registry's words

- Brief title: Assessment of the WATCHMAN™ Device in Patients Unsuitable for Oral Anticoagulation
- Acronym: ASAP-TOO
- Condition: Stroke
- Intervention (Device): WATCHMAN LAAC Device Implant
- Intervention (Drug): Single Antiplatelet Therapy or No Therapy (Control)
- Lead sponsor: Boston Scientific Corporation
- Lead sponsor class: INDUSTRY

## Connected pages

- Registry condition terms include this condition: Stroke (`core:stroke`)
- Registry lists this organization as the lead sponsor: Boston Scientific (`cardio:boston-scientific`)

## Provenance

Content hash: b7e2eea181562188b41e565cea26730a6f7f5e2035256253770397e4ed255df9
Last substantive edit: 2026-10-26
Evidence last checked: Not recorded
